ARTICLE | Clinical News
PA32540: Phase III data
March 26, 2012 7:00 AM UTC
Top-line data from a pair of double-blind, U.S. Phase III trials in a total of 1,049 patients showed that once-daily oral PA32540 met the primary endpoint in both trials of reducing the cumulative inc...